Linsitinib

Drug Profile

Linsitinib

Alternative Names: ASP-7487; OSI-906; OSI-906AA

Latest Information Update: 30 Mar 2017

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Multiple Myeloma Research Foundation
  • Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
  • Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple myeloma
  • Discontinued Adrenocortical carcinoma; Hepatocellular carcinoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 08 Aug 2016 No development reported - Phase-I/II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada, USA (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 12 May 2014 Discontinued - Phase-II for Ovarian cancer in USA, Canada, Switzerland, United Kingdom, Australia, Italy, Poland, Romania and Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top